Cargando…
P-Glycoprotein Mediated Efflux Limits the Transport of the Novel Anti-Parkinson's Disease Candidate Drug FLZ across the Physiological and PD Pathological In Vitro BBB Models
FLZ, a novel anti-Parkinson's disease (PD) candidate drug, has shown poor blood-brain barrier (BBB) penetration based on the pharmacokinetic study using rat brain. P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are two important transporters obstructing substrates entry into...
Autores principales: | Liu, Qian, Hou, Jinfeng, Chen, Xiaoguang, Liu, Gengtao, Zhang, Dan, Sun, Hua, Zhang, Jinlan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103815/ https://www.ncbi.nlm.nih.gov/pubmed/25036090 http://dx.doi.org/10.1371/journal.pone.0102442 |
Ejemplares similares
-
An In Vivo Microdialysis Study of FLZ Penetration through the Blood-Brain Barrier in Normal and 6-Hydroxydopamine Induced Parkinson's Disease Model Rats
por: Hou, Jinfeng, et al.
Publicado: (2014) -
Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity
por: Zhang, Dan, et al.
Publicado: (2008) -
Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment
por: Shang, Junmei, et al.
Publicado: (2021) -
Genome-wide Identification and Characterization of FCS-Like Zinc Finger (FLZ) Family Genes in Maize (Zea mays) and Functional Analysis of ZmFLZ25 in Plant Abscisic Acid Response
por: Chen, Shunquan, et al.
Publicado: (2021) -
Squamosamide Derivative FLZ Diminishes Aberrant Mitochondrial Fission by Inhibiting Dynamin-Related Protein 1
por: Yang, Hanyu, et al.
Publicado: (2021)